Escozine Hp

Rhopalurus Princeps Venom, Bryonia Alba,echinacea Purpurea


Medolife Corporation
Human Otc Drug
NDC 70891-201
Escozine Hp also known as Rhopalurus Princeps Venom, Bryonia Alba,echinacea Purpurea is a human otc drug labeled by 'Medolife Corporation'. National Drug Code (NDC) number for Escozine Hp is 70891-201. This drug is available in dosage form of Liquid. The names of the active, medicinal ingredients in Escozine Hp drug includes Bryonia Alba Root - 30 [hp_C]/mL Echinacea Purpurea - 10 [hp_X]/mL Rhopalurus Princeps Venom - 3 [hp_X]/mL . The currest status of Escozine Hp drug is Active.

Drug Information:

Drug NDC: 70891-201
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Escozine Hp
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Rhopalurus Princeps Venom, Bryonia Alba,echinacea Purpurea
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Medolife Corporation
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Liquid
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:BRYONIA ALBA ROOT - 30 [hp_C]/mL
ECHINACEA PURPUREA - 10 [hp_X]/mL
RHOPALURUS PRINCEPS VENOM - 3 [hp_X]/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 30 Sep, 2016
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 19 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Medolife Corporation
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:T7J046YI2B
QI7G114Y98
1A0769Q0NA
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
70891-201-011 BOTTLE in 1 CARTON (70891-201-01) / 120 mL in 1 BOTTLE30 Sep, 2016N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose: rhopalurus princeps venom 3x..pain, inflammation bryonia alba 30c .............relieves pain echinacea purpurea 10x........relieves inflammation

Product Elements:

Escozine hp rhopalurus princeps venom, bryonia alba,echinacea purpurea echinacea purpurea echinacea purpurea water bryonia alba root bryonia alba root rhopalurus princeps venom rhopalurus princeps venom

Indications and Usage:

Indications: uses relieves pain improves energy improves sleep relieves inflammation improves appetite

Warnings:

Warnings: do not use if the tamper evident strip is broken or removed from the base of the cap.

When Using:

When using this product: when using this product: you may experience fatigue you may experience temporary darkening of urine you may experience temporary diarrhea avoid dairy products for 2 hours before and after intake

Dosage and Administration:

Directions: directions adults and children 12 years and over: take 1 ml 20 minutes before meals; not more than 4 ml in 24 hours children 6 years to 12 years children: take 0.50 ml 20 minutes before meals ; not more than 2 ml in 24 hours under 6 years ask a doctor

Stop Use:

Stop use and ask doctor if you experience worsening symptoms symptoms last longer than 7 days.

Package Label Principal Display Panel:

Package label display: principal display panel box label

Further Questions:

Questions: medolife corporation 1-800-859-7036 info@medolife.com


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.